23 May '23
Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 months Sustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted
06 May '23
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery alone MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.
20 Apr '23
MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended
03 Apr '23
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison
13 Mar '23
MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the
Displaying 1 - 10 of 15